{"id":"eplerenone-vs-amlodipine","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Hyperkalemia"},{"rate":"1-2","effect":"Gynecomastia"},{"rate":"5-15","effect":"Peripheral edema"},{"rate":"5-10","effect":"Headache"},{"rate":"3-8","effect":"Flushing"},{"rate":"2-5","effect":"Dizziness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Eplerenone blocks aldosterone receptors in the kidney and heart, reducing sodium retention and blood volume while providing cardiac protection in heart failure and post-MI settings. Amlodipine blocks L-type calcium channels in vascular smooth muscle, causing vasodilation and reducing peripheral vascular resistance to lower blood pressure. These agents represent different mechanistic approaches to hypertension and cardiovascular disease management.","oneSentence":"This is a comparison of two marketed cardiovascular drugs: eplerenone, a selective aldosterone antagonist, and amlodipine, a calcium channel blocker, each working through different pathways to lower blood pressure.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:45:39.735Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension (both agents)"},{"name":"Heart failure with reduced ejection fraction (eplerenone)"},{"name":"Post-myocardial infarction with left ventricular dysfunction (eplerenone)"},{"name":"Angina pectoris (amlodipine)"}]},"trialDetails":[{"nctId":"NCT03683069","phase":"PHASE4","title":"Mineralocorticoid Receptor (MR) Antagonist (Eplerenone) vs Amlodipine and STRIATIN","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2019-01-15","conditions":"Hypertension, Genetics Hypertension","enrollment":90},{"nctId":"NCT04467931","phase":"","title":"ACEI or ARB and COVID-19 Severity and Mortality in US Veterans","status":"COMPLETED","sponsor":"University of Utah","startDate":"2020-01-19","conditions":"Hypertension, COVID","enrollment":22213}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Eplerenone vs Amlodipine","genericName":"Eplerenone vs Amlodipine","companyName":"Brigham and Women's Hospital","companyId":"brigham-and-women-s-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a comparison of two marketed cardiovascular drugs: eplerenone, a selective aldosterone antagonist, and amlodipine, a calcium channel blocker, each working through different pathways to lower blood pressure. Used for Hypertension (both agents), Heart failure with reduced ejection fraction (eplerenone), Post-myocardial infarction with left ventricular dysfunction (eplerenone).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}